Panacea Biotec Reports Strong December 2024 Results Amid Concerns Over Non-Operating Income
Panacea Biotec has announced its financial results for the quarter ending December 2024, showcasing significant year-on-year growth in Profit After Tax and net sales, alongside improved operating profit and margin. However, the high proportion of non-operating income raises concerns about the sustainability of its financial performance.
Panacea Biotec, a small-cap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results, declared on February 14, 2025, indicate a notable shift in the company's evaluation, with its score rising to 13 from 10 over the past three months.The financial data reveals several positive trends for Panacea Biotec. The Profit After Tax (PAT) for the quarter stands at Rs 1.75 crore, reflecting a significant year-on-year growth of 134.6%. Additionally, net sales reached Rs 163.49 crore, marking the highest figure in the last five quarters. The operating profit also saw an uptick, recorded at Rs 7.96 crore, which is the highest in the same timeframe. Furthermore, the operating profit margin improved to 4.87%, indicating enhanced efficiency within the company.
However, there are aspects that raise concerns. The non-operating income constitutes 224.84% of the Profit Before Tax (PBT), suggesting a reliance on income from non-business activities, which may not be sustainable in the long run.
For more insights on Panacea Biotec's financial performance and evaluation changes, visit: Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
